All News

Meeting audience conference

ACR 2024 - Day 1 Report

Jack Cush, MD

ACR Convergence 2024 opened today with a full slate of presentations, posters and specialty meetings.  The meeting began with a flip: the plenary sessions started at 9AM and the poster session began at 1030 AM. Below are some of the highlights from day one in Washington, DC.

Read Article
temperature.fever_.weather.jpg

A Polygenic Model for Still's Disease

Jack Cush, MD

Adult-onset Still's disease (AOSD) is systemic autoinflammatory disorder of unknown etiology.  It is considered among the febrile autoinflammatory etiologies.

Read Article
biosimilars2.jpg

Biosimilar Slow Growth in USA

Jack Cush, MD

A recent Forbes article, "Biosimilars Are Making Inroads In U.S., But It’s Still A Bumpy Ride", reviews the current state and reasons for slowish uptake of these significant cost-savings alternatives to biologic therapy in treating cancer and autoimmune disorders. The following are takeaway bullets from this informative article.

Read Article
Liver.hepatitis.jpg

Advances in the treatment of autoimmune hepatitis

EurekAlert!

Autoimmune hepatitis (AIH) is a chronic, progressive liver disease caused by immune system dysregulation that targets the liver. If untreated, AIH can lead to severe complications, including cirrhosis and liver failure. 

Read Article
Cutaneous.lupus.SLE.Face.dermnetnz

Iberdomide Efficacy in Cutaneous Lupus

Jack Cush, MD

Iberdomide, a cereblon modulator that promotes degradation of transcription factors Ikaros and Aiolos, has been shown in a phase 2 trial to improve outcomes in subacute and chronic cutaneous lupus erythematosus (CLE).

Read Article
Knee,pain,OA,DJD

GLP-1 Inhibitor Reduces Knee Osteoarthritis Pain

MedPage Today

Semaglutide (Wegovy) reduced pain and improved physical function in patients with obesity and knee osteoarthritis, a randomized trial showed.

Read Article
RA.Ow02.jpg

Filgotinib Efficacy and Safety - 3 Years Later

MedPage Today

Filgotinib, the rheumatoid arthritis (RA) oral drug that never made it to the U.S. market but is sold across Europe, Great Britain, and Japan, remained effective for 3 years for most registration trial participants who continued in a long-term extension study, researchers said.

Read Article

Impressive Plenary @andreafava just finished Novel urine protein panel id 12 proteins that predict NIH activity on renal bx better than existing options Improving at 3 mos predicts response at 1 year Could reduce biopsies / modulate tx! #ACR24 @RheumNow Abstr#1642 #ACRbest https://t.co/Gi6u6hAGzj

Links:

Mike Putman EBRheum ( View Tweet)
"We look forward to Carol Langfords upcoming leadership at ACR and its newfound focus on ANCA vasculitis as the most important disease" 😆😂 -Phil Seo #ACR24 @RheumNow

Mike Putman EBRheum ( View Tweet)

Starting soon: Room 152A ⁦@ACRheumDC⁩ ⁦@cdowneymd⁩ ⁦@BelindaBirnbaum⁩ What does the election and current political changes mean for rheumatology? How does ACR play a role in supporting you? What are the easy steps you can do? #ACR24 ⁦@RheumNow⁩ https://t.co/jTtk80RdqI

Links:

Eric Dein ericdeinmd ( View Tweet)
RheumNow’s expanded coverage of the #ACR24 annual meeting is sponsored in part by Novartis. All content is chosen by RheumNow & its faculty.

Dr. John Cush RheumNow ( View Tweet)

Phase 2 DBRCT of daxdilimab, an immunoglobulin-like transcript 7 to target plasmacytoid dendritic cells No difference in primary outcome... but kiiiinda looks like something there? I dislike Phase 2's; should go straight to Phase 3 if able #ACR24 @rheumnow Abstr#1542 https://t.co/osDWDskfnA

Links:

Mike Putman EBRheum ( View Tweet)
RheumNow’s expanded coverage of the #ACR24 meeting is sponsored in part by Novartis. All content is chosen by RheumNow & its faculty.

Dr. John Cush RheumNow ( View Tweet)

RheumNow’s expanded coverage of the #ACR24 Annual meeting is sponsored in part by Bristol Myers Squibb and UCB. All content is chosen by RheumNow & its faculty.

Dr. John Cush RheumNow ( View Tweet)

#0509 📊 RA DMARD Trends in US (2001-2021) 🧑‍🤝‍🧑 407,728 DMARD starts in 229,365 patients 📉 csDMARD use fell (79.7% → 54.7%) ‼️Methotrexate dropped 29% → 15% 📈 bDMARDs (20.3% →33.1%),tsDMARDs (0.1% → 12.2%) both ⬆️⬆️ 💊Biosimilar uptake low #ACR24 @RheumNow @jeffsparks https://t.co/JepaWj7azY

Links:

Caoilfhionn Connolly CaoilfhionnMD ( View Tweet)
Like we've seen in many parts of the world, RA prescribing in Germany is moving away from JAKi, in response to regulatory safety warnings. Whether all of this is appropriate or not, we'll have to see... #ACR24 ABST0503 @RheumNow https://t.co/VSqdCz6zc5

Links:

David Liew drdavidliew ( View Tweet)
Biosimilar Slow Growth in USA A recent Forbes article, "Biosimilars Are Making Inroads In U.S., But It’s Still A Bumpy Ride", reviews the current state and reasons for slowish uptake of these significant cost-savings alternatives to biologic therapy in treating cancer and… https://t.co/yO3tUVk2jj https://t.co/ft6gqpnWMx
Dr. John Cush RheumNow ( View Tweet)
FDA has given FDA Breakthrough Therapy designation to Nipocalimab for treatment of adults w/ moderate-to-severe Sjögren’s disease. NIPO is an Ab to neonatal Fc receptor (FcRn), & was tested and shown effective in Sjog in the Phase 2 DAHLIAS study - a plenary presentation at… https://t.co/Nq09iEoxJ9 https://t.co/JG4P8zMw9j
Dr. John Cush RheumNow ( View Tweet)
FDA's perspective on the use of artificial intelligence in drug development. - FDA is committed to a risk-based regulatory framework that promotes innovation & protects Pt safety - Est. CDER AI Council to coordinate, develop, & support internal & external AI-related activities… https://t.co/BLCYmBBJMY https://t.co/fMie3oOfmn
Dr. John Cush RheumNow ( View Tweet)
Fasenra approved in the EU for eosinophilic granulomatosis with polyangiitis https://t.co/luhFvy3yjR https://t.co/52oiTYG3a4

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×